



Research Article

Bioinformatics-Based Identification of CircRNA-MicroRNA-mRNA Network for Calcific Aortic Valve Disease

Linghong Song,¹ Yubing Wang,¹ Yufei Feng,¹ Hao Peng,¹ Chengyan Wang,¹ Juncang Duan,² Kejian Liu,³ Xihua Shen,¹ Wenyi Gu,⁴ Yan Qi,^{1,5} Shan Jin ¹, and Lijuan Pang ^{1,5}

¹NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases (First Affiliated Hospital, School of Medicine, Shihezi University), Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, Xinjiang, China

²Department of Cardiology, Jinhua Municipal Central Hospital, Jinhua, Zhejiang, China

³Department of Cardiology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang, China

⁴Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Australia

⁵Department of Pathology, Central People's Hospital of Zhanjiang and Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, Guangdong, China

Correspondence should be addressed to Shan Jin; jinshanqingdao@sina.com and Lijuan Pang; ocean123456@163.com

Linghong Song, Yubing Wang, and Yufei Feng contributed equally to this work.

Received 18 September 2022; Revised 13 February 2023; Accepted 24 April 2023; Published 17 May 2023

Academic Editor: Abd El-Latif Hesham

Copyright © 2023 Linghong Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Calcific aortic valve disease (CAVD) is the most common native valve disease. Valvular interstitial cell (VIC) osteogenic differentiation and valvular endothelial cell (VEC) dysfunction are key steps in CAVD progression. Circular RNA (circRNAs) is involved in regulating osteogenic differentiation with mesenchymal cells and is associated with multiple disease progression, but the function of circRNAs in CAVD remains unknown. Here, we aimed to investigate the effect and potential significance of circRNA-miRNA-mRNA networks in CAVD. **Methods.** Two mRNA datasets, one miRNA dataset, and one circRNA dataset of CAVD downloaded from GEO were used to identify DE-circRNAs, DE-miRNAs, and DE-mRNAs. Based on the online website prediction function, the common mRNAs (FmRNAs) for constructing circRNA-miRNA-mRNA networks were identified. GO and KEGG enrichment analyses were performed on FmRNAs. In addition, hub genes were identified by PPI networks. Based on the expression of each data set, the circRNA-miRNA-hub gene network was constructed by Cytoscape (version 3.6.1). **Results.** 32 DE-circRNAs, 206 DE-miRNAs, and 2170 DE-mRNAs were identified. Fifty-nine FmRNAs were obtained by intersection. The KEGG pathway analysis of FmRNAs was enriched in pathways in cancer, JAK-STAT signaling pathway, cell cycle, and MAPK signaling pathway. Meanwhile, transcription, nucleolus, and protein homodimerization activity were significantly enriched in GO analysis. Eight hub genes were identified based on the PPI network. Three possible regulatory networks in CAVD disease were obtained based on the biological functions of circRNAs including: *hsa_circ_0026817-hsa-miR-211-5p-CACNA1C*, *hsa_circ_0007215-hsa-miR-1252-5p-MECP2*, and *hsa_circ_0007215-hsa-miR-1343-3p-RBL1*. **Conclusion.** The present bioinformatics analysis suggests the functional effect for the circRNA-miRNA-mRNA network in CAVD pathogenesis and provides new targets for therapeutics.

1. Introduction

Calcific aortic valve disease (CAVD) is a condition caused by calcification of the aortic valve or aortic annulus, resulting in a hemodynamic manifestation of aortic valve stenosis or regurgitation [1]. It is a chronic progressive disease that

increases in prevalence with age [2, 3], leading to an increasing proportion of acquired valvular heart disease. CAVD has become a significant factor of disease burden in the elderly [4], which has the characteristics of high morbidity and mortality [1]. Treatment of CAVD mainly relies on surgery [5], which includes surgical valve replacement

and percutaneous valve prosthetic implantation. However, not all patients are eligible for surgical treatment. In terms of drug therapy, the antihypertensive drugs and statins are effective in treating atherosclerosis but do not reverse or slow the process of CAVD [6]. In conclusion, there is an urgent need to explore the key regulatory molecules in the pathogenesis of CAVD to provide new targets for its pharmacological treatment.

About 90% of the mammalian genome is transcribed into noncoding RNAs (ncRNAs), whose functions have not been fully studied [7]. With the development of deep RNA sequencing (RNA-seq) technology and novel bioinformatics methods, a wide variety of circular RNAs (circRNAs) types have been discovered and identified [8]. As a series of novel noncoding RNAs, circRNAs are characterized by a covalent closed loop structures lacking a 5' cap or a 3' Poly A tail [9]. The high abundance, relative stability, and evolutionary conservation of circRNAs distinguish it from traditional linear RNAs. CircRNAs has significant advantages in developing applications as a novel clinical diagnostic marker because it is able to better adsorb miRNAs from organisms than linear mRNAs and lncRNAs. However, the function of circRNAs is still unclear. There is growing evidence that belongs to competing endogenous RNAs (ceRNAs), which contain microRNA response elements (MREs). The specific RNAs with MREs can impair miRNA activity by sequestration, resulting in upregulation of miRNA target gene expression, which is known as ceRNA hypothesis [10]. The circRNAs has been found to exert an important biological response in cardiovascular disease [11–13], but studies on CAVD are still limited. Wang et al. found that circRIC3, as a miR-204-5p sponge, positively regulates the expression of the calcification-promoting gene dipeptidyl peptidase-4 (DPP4), leading to CAVD [1]. Yu et al. reported that circRNA TGFBR2 positively regulates TWIST1 through sponge phagocytosis of miR-25-3p by inhibiting osteoblast differentiation and preventing valve calcification in human VICs [14]. These results reconfirm that circRNAs are critical in the development of CAVD. However, studies on circRNA-associated ceRNA networks in CAVD remain scarce. Therefore, studying of circRNA-miRNA-mRNA networks complements the lack of ncRNA in the exploration of CAVD pathogenesis. It is promising to find markers that can be used as diagnostic predictors of the disease and provide new insights for the treatment of CAVD.

To investigate how the circRNA-miRNA-mRNA network regulates CAVD pathophysiological processes, we gain insight into the signaling regulation within the tissues leading to involvement in CAVD progression and discover relevant therapeutic targets. We screened CAVD-related circRNA, miRNA, and mRNA datasets in the Gene Expression Omnibus (GEO) database (Figure 1). By performing differential expression analysis, DE-circRNAs and DE-miRNAs targets were predicted. Following that, we constructed circRNA-miRNA-mRNA networks in CAVD. The common mRNAs (FmRNAs) were analyzed by gene ontology (GO) function enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and protein-protein interaction (PPI) network construction.

We identified 8 hub genes from PPI for circRNA-miRNA-hub gene network visualization, and this regulatory network will be a potential therapeutic target for treating CAVD diseases. The schema of the bioinformatics analysis is shown in Figure 1.

2. Methods

2.1. RNA Array. The CAVD datasets from the National Center for Biotechnology Information (NCBI) GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) were evaluated and screened. The GSE155119 dataset of circRNA expression was found in GPL26192 platform. The GSE87885 dataset of miRNA expression was found at GPL22555 platform. On the GPL10558 platform and GPL570 platform, we found the GSE83453 and GSE51472 datasets for mRNA expression. The calcified aortic valve contains 20 samples, including 3 circRNA samples, 2 miRNA samples, and 15 mRNA samples. The noncalcified aortic valve contains 19 samples, with 3 from the circRNA dataset, 3 from the miRNA dataset, and 13 from the mRNA dataset.

2.2. Screening for Differential Expression. Microarray datasets that provide RNA expression profile data in CAVD were imported into the R software and standardized with “impute” package [15–18]. The “LIMMA” package running in the R software analyzed the data for differential expression. $|\log \text{Fold Change}| > 2$ and $p\text{-value} < 0.001$ were considered to indicate significant differentially expressed circRNAs (DE-circRNAs). $p\text{-value} < 0.05$ was considered to screen differentially expressed miRNAs (DE-miRNAs) and mRNAs (DE-mRNAs).

2.3. Prediction of DE-CircRNAs and DE-miRNAs Targets. The DE-circRNAs target miRNAs were predicted by using the online software, the Encyclopedia of RNA Interactomes (ENCORI). DE-miRNAs target genes were predicted by online websites, miRTarBase, TargetScan, and miRDB (Table 1), respectively. The mRNAs recognized by miRTarBase, TargetScan, and miRDB websites were considered candidate targets. The information of websites is shown in Table 1.

2.4. CircRNA-miRNA-mRNA Network. The common DE-miRNAs (ICPDEmiRNAs) were obtained from the intersection of DE-circRNA targets and the DE-miRNAs. Similarly, common DE-mRNAs (FmRNAs) were obtained by intersecting ICPDEmiRNAs targets with DE-mRNAs. Based on DE-circRNAs, ICPDEmiRNAs, and FmRNAs, we constructed circRNA-miRNA-mRNA network, which was visualized using Cytoscape software (version 3.6.1).

2.5. GO Function Analysis. The database for annotation, visualization, and integrated discovery (DAVID, <https://david.ncicrf.gov/>) is an online web-based bioinformatics resource, which can provide tools for analyzing the function of large lists of genes/proteins [19]. The FmRNAs were input into DAVID online software to annotate the target genes with GO function. The results are visualized by R software.




FIGURE 1: The schema of the bioinformatics analysis.

TABLE 1: Websites for circRNA and miRNA targets prediction.

Name	Website
miRTarBase	https://mirtarbase.mbc.nctu.edu.tw/php/index.php
TargetScan	https://www.targetscan.org/vert/
miRDB	https://mirdb.org/
ENCORI	https://starbase.sysu.edu.cn/index.php
Bioinformatics & Evolutionary Genomics	https://bioinformatics.psb.ugent.be/webtools/Venn/

2.6. KEGG Pathway Analysis. KEGG Orthology-Based Annotation System (KOBAS) is one of the most widely used web servers for gene/protein functional annotation and gene set enrichment. The KOBAS website was used to map FmRNAs to the KEGG pathway. KEGG pathway analysis visualization was performed using R software.

2.7. PPI Network. STRING (<https://string-db.org/>) database is the software for predicting protein-protein interactions. The PPI network of FmRNAs was established using the STRING database (version 11.0). A combined score of >0.4 was considered the cutoff to indicate a significant PPI pair.

2.8. CircRNA-miRNA-Hub Gene Network. Eight FmRNAs with a high degree of PPI were selected to find the relevant noncoding RNAs regulating them from the total DE-circRNAs and DE-miRNAs. These relevant data were imported into Cytoscape software (version 3.6.1) for analysis and visual graphing.

3. Results

3.1. Differential Expression of RNA Array. The “LIMMA” package is derived from R software, which allows analysis of differential expression in datasets. Thirty-two DE-circRNAs, 206 DE-miRNAs, and 2170 DE-mRNAs in the calcified




FIGURE 2: Differentially expressed RNAs. (a) Volcano plot of DE-circRNAs. Green represents down-regulation and red represents up-regulation. (b) Heatmap of 32 DE-circRNAs, p -value <0.001 . (c) Heatmap of the DE-miRNAs with the most obvious up-regulation and down-regulation, p -value <0.05 . (d) It is a heat map of DE-mRNAs, which is the most significant up-regulation and down-regulation, p -value <0.05 . Darker colors indicate up-regulation, while lighter colors indicate down-regulation.

aortic valve samples were compared with the uncalcified aortic valve samples. The DE-circRNAs are shown in Figures 2(a) and 2(b). DE-miRNAs (Figure 2(c)) and DE-mRNAs (Figure 2(d)) were visualized. For better display of the results, we selected the top 20 significantly upregulated and downregulated ones in order to show the statistically significant.

3.2. Construction of CircRNA-miRNA-mRNA Network. There were 289 DE-circRNAs targets miRNAs predicted by ENCORI. Twenty common miRNAs (ICPDEmiRNAs) were obtained by intersecting DE-miRNAs with DE-circRNAs targets (Figure 3(a)). These 20 ICPDEmiRNAs were subjected to target gene prediction in miRBase, TargetScan, and miRDB websites, and 474 target mRNAs were obtained. The 59 common mRNAs (FmRNAs) were the intersection of ICPDEmiRNAs targets with DE-mRNAs (Figure 3(b)). Subsequently, the circRNA-miRNA-mRNA network was

constructed, which contains 12 DE-circRNAs, 12 DE-miRNAs, and 59 DE-mRNAs (Figure 3(c)).

3.3. GO Function Analysis. GO functional annotation was used to analyze FmRNAs. Three GO categories were analyzed including biological processes (BP), molecular functions (MF), and cellular components (CC) (Figure 4). The 59 FmRNAs in the BP terms annotation function in GO mainly include transcription, DNA-templated, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription from RNA polymerase II promoter, negative regulation of transcription, DNA-templated, positive regulation of cell proliferation (Figure 4(a)), nucleolus, endoplasmic reticulum membrane, nucleus, heterochromatin, neuronal cell body, and plasma membrane in the CC terms (Figure 4(b)). Protein homodimerization activity, transcription factor activity, sequence-specific DNA binding,




FIGURE 3: (a) Venn diagram of 206 DE-miRNAs and 289 DE-circRNAs targeting miRNAs. (b) Venn diagram of 474 target genes and 2170 DE-mRNAs predicted by ICPDEmiRNAs. (c) Construction of circRNA-miRNA-mRNA network. The diamond, triangle and oval shapes respectively circRNAs, miRNAs and mRNAs.

transcription factor binding, protein domain specific binding, and chromatin binding pertained to the MF terms (Figure 4(c)).

3.4. KEGG Pathway Enrichment Analysis. Understanding the enrichment pathways of these FmRNAs can gain further insight into the significance in CAVD. The KEGG pathway was




FIGURE 4: GO analysis for 59 FmRNAs. (a) Enrichment analysis on GO BP item. (b) Enrichment analysis on GO CC item. (c) Enrichment analysis on GO MF item.

used for enrichment analysis of these FmRNAs (Figure 5). FmRNAs are primarily involved in cancer pathway, JAK-STAT signaling pathway, and cell cycle and MAPK signaling pathway in KEGG pathway analysis.

3.5. *PPI Network.* Target gene data predicted by FmRNAs were uploaded to the STRING database for the construction of the PPI network (Figure 6). The MYC, ITPR1, EGFR, CACNA1C, RASGRP1, MECP2, RBL1, and WEE1 were the




FIGURE 5: KEGG pathway analysis of FmRNAs. The larger the dot, the greater the degree and the richer the number of genes.

hub genes with high degree values. The hub genes expression was shown in Figure 7.

3.6. Construction of CircRNA-miRNA-Hub Gene Network. According to the PPI network, the 8 hub genes were obtained. In order to investigate the regulatory network, Cytoscape software (version 3.6.1) was used to construct and visualize these hub genes for the circRNA-miRNA-hub gene network (Figure 8). Based on the “miRNA sponge” function of circRNA, three groups of circRNA-miRNA-hub gene regulatory networks were identified including hsa_circ_0026817-hsa-miR-211-5p-CACNA1C, hsa_circ_0007215-hsa-miR-1252-5p-MECP2, and hsa_circ_0007215-hsa-miR-1343-3p-RBL1.

4. Discussion

CAVD, the most common valvular disorder, is the leading cause of aortic stenosis. The most effective treatment is surgery or interventional valve replacement [20], which has

complications and does not guarantee long-term success [21]. There is an absence of approved pharmacological treatments to stop the progression or treat CAVD [22]. The ceRNA hypothesis has been proposed as a model for regulating gene expression during disease progression in recent years [10]. There is growing experimental evidence that multiple noncoding RNAs, including circRNAs, small noncoding RNAs, pseudogenes, and lncRNAs may have ceRNA activity [23]. More importantly, circRNAs, which are highly resistant to nucleases, maintain high abundance in the cytoplasm and better regulate miRNAs. However, it was only circRIC3 and circRNA TGFBR2 that were studied in CAVD disease [1, 14]. Construction of circRNA-miRNA-mRNA regulatory networks is essential to understand the pathophysiological progression of CAVD as the basis for developing novel therapeutics.

We have constructed circRNA-miRNA-mRNA regulatory networks based on the sponge activity of circRNA. Most circRNAs in the coexpression network remain unknown.




FIGURE 6: (a) FmRNAs PPI network. The protein corresponding to the FmRNAs is expressed through the circle, and the line represents the relationship between the protein and the protein. The more lines, the more important the protein. (b) Histogram of degree values in PPI networks.

Bioinformatic analysis of the DE-circRNAs target genes in network showed that transcription was the most important BP identified by GO analysis. Vadana et al. found that expression of SMAD and Runt transcription factors increased calcium deposition in CAVD [24]. The KEGG pathway of the target gene is significantly enriched in the cell cycle, MAPK and TGF- β pathway. It has been previously shown that MAP2K1 mutations activate p-ERK-dependent cell cycle progression and autophagy, exhibiting arterial valve stenosis [25]. Inhibiting the p38-MAPK signaling pathway can reduce ALP activity and calcification deposition to ameliorate aortic valve calcification [26].

We successfully established 3 circRNA-miRNA-hub gene networks relevant to CAVD, which include hsa_circ_0026817-hsa-miR-211-5p-CACNA1C, hsa_circ_0007215-hsa-miR-1343-3p-RBL1, and hsa_circ_0007215-hsa-miR-1252-5p-MECP2. Normal aortic valves are composed of valve endothelial cells (VECs) and valve interstitial cells (VICs), which play an important role in maintaining valve morphology and function [27]. Dysfunction of VICs and VECs is the key to the progression of CAVD. Upregulated hsa_circ_0026817 in CAVD may target hsa-miR-211-5p to regulate CACNA1C. It has been shown that miR-211-5p overexpression inhibits cell cycle by decreasing

cyclin D1 levels [28]. Inhibition of cyclin D1 essentially abolishes fibrotic responses which are associated with VICs proliferation [29, 30]. Downregulation of miR-211-5p in CAVD leads to aortic valve fibrosis via the regulation of cyclin D1 in VICs. CACNA1C is the gene encoding the L-type voltage-gated Ca^{2+} channel [31]. The activation of cytosolic L-type Ca^{2+} channel leads to the entry of small amounts of Ca^{2+} into the cytoplasm and triggers Ca^{2+} release from the sarcoplasmic reticulum by activating ryanodine receptor 2 (RyR2). RyR2 was predominantly expressed in VICs, and inhibition of RyR2 prevents valvular calcification [32]. Matsui et al. identified high expression of CACNA1C in calcified valves and verified the involvement of CACNA1C in CAVD progression by affecting valve calcification in VIC cells [33].

Down-regulated hsa_circ_0007215 in CAVD may regulate both hsa-miR-1343-3p/RBL1 and hsa-miR-1252-5p/MECP2. Upregulated miR-1343-3p in CAVD might directly influence valve endothelial cells (VECs) growth through the TGF- β signaling pathway. The surface of the heart valves is covered with VECs [34], which forms a barrier between the blood and the internal valve tissue [35]. In the aortic valve, TGF- β 1 is predominantly localized to VEC and found to decrease the phosphorylation of RBL1 at the G1/S boundary,




FIGURE 7: Eight hub genes expression in CAVD mRNA dataset. * $p < 0.05$, ** $p < 0.01$, **** $p < 0.001$.




FIGURE 8: The circRNA-miRNA-hub gene regulatory network. The diamond, triangle and oval shapes respectively circRNAs, miRNAs and mRNAs. Green represents downregulated RNAs, red represents upregulated RNAs.

thereby inhibiting the development of cells into S phase [36, 37]. hsa-miR-1343-3p/RBL1 pathway was involved in CAVD by regulating the VECs cycle. Overexpression of miR-1252-5p might take part in CAVD by promoting MAPK signaling pathway [38], which has been shown to be involved in regulating Ca^{2+} entry into cells and mediating osteogenic differentiation of VIC in CAVD [39, 40]. MECP2, a target gene of miR-1252-5p, is an important regulator for the maintenance of normal cardiac development and myocardial structure [41]. The shorter e2 splice isoform of MECP2 can activate the MAPK pathway [42], which is

involved in determining the structure of healthy heart [43]. Our findings suggest that 3 circRNA-miRNA-mRNA networks could be contributing factors for CAVD.

In conclusion, the pathogenic effects of the ceRNA network in CAVD may be associated with the regulation of VICs and VECs. The identified 3 circRNA-miRNA-hub gene axes may constitute the underlying pathophysiology of CAVD (Figure 9). This offers new insights into pharmacological interventions for CAVD. In considering the multiple factors that are responsible for CAVD disease, including collagen accumulation and resident cytopathic




FIGURE 9: Schematic representation of the role of three circRNA-miRNA-mRNA regulatory networks in promoting CAVD. Has_circ_0026817-hsa-miR-211-5p-CACNA1C encodes enhanced L-type calcium channels that promote calcium influx into VICs, leading to calcification. In addition, hsa_circ_0026817 targets hsa-miR-211-5p through sponge activity, regulates cyclin D1, and promotes proliferation of VICs. Hsa_circ_0007215-hsa-miR-1252-5p-MECP2 regulates calcium channels through the MAPK pathway and is involved in calcification of VICs. Hsa_circ_0007215-hsa-miR-1343-3p-RBL1 is regulated by TGF- β signaling. RBL1 is inhibited in VEC, blocking G1-S phase cell cycle progression and regulating VECs proliferation. In hsa_circ_0007215-hsa-miR-1343-3p-RBL1, TGF- β signaling is able to regulate RBL1 to block cell cycle progression in G1-S phase and regulate proliferation of VECs.

remodeling [44], these circRNA-miRNA-mRNA axes could also be involved in CAVD formation. We addressed this issue through further analysis; hsa_circ_0026817-hsa-miR-211-5p-CACNA1C, hsa_circ_0007215-hsa-miR-1343-3p-RBL1, and hsa_circ_0007215-hsa-miR-1252-5p-MECP2 may be a new effective and potential target for the treatment of CAVD.

5. Conclusion

The establishment of CAVD is a result of the contribution of multiple regulatory factors. We constructed the circRNA-miRNA-mRNA regulatory network by microarray data mining and comprehensive bioinformatics analysis. It reveals that hsa_circ_0026817-hsa-miR-211-5p-CACNA1C, hsa_circ_0007215-hsa-miR-1252-5p-MECP2, and hsa_circ_0007215-hsa-miR-1343-3p-RBL1 axes may play a crucial part in CAVD and may provide new insights into the pathogenesis and therapeutic targeting of CAVD.

Data Availability

The data used in this study are publicly available and allow unrestricted reuse through open licenses. All datasets in this study were downloaded from the GEO database. These datasets were taken from the following public domain resources: <https://www.ncbi.nlm.nih.gov/geo/>. The GEO

public database allows researchers to download and analyze public datasets for scientific purposes.

Disclosure

Linghong Song, Yubing Wang and Yufei Feng were the co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

LS, YW, and YF were responsible for the reliability of the submitted data and drafted the article. HP, SJ, CW, and JD performed the statistical analysis and interpretation of the data. XS, YQ, and WG were responsible for the evaluation and guidance of the full text. LP provided final approval of the submitted version. All authors read and approved the final manuscript. Linghong Song, Yubing Wang, and Yufei Feng contributed equally.

Acknowledgments

The authors would like to express their gratitude to all participants in this study. The authors acknowledge GEO database for providing their platforms and contributors for

uploading their meaningful datasets. This work was supported by the National Natural Science Foundation of China (82060054), Science and Technology Cooperation Project of Corps (2020BC003), Science Research Projects of Shihezi University (ZZZC202022A), the Discipline Construction Fund of Central People's Hospital of Zhanjiang (2022A15, 2022A16), High-Level Hospital Construction of Key Projects of Disease Prevention and Control (2022A01103), the Zhanjiang Science and Technology Special Fund Project for Basic Research (2022A01028), and Xinjiang Autonomous Region Postgraduate Research Innovation Project (XJ2022G110).

References

- [1] Y. Wang, D. Han, T. Zhou et al., "Melatonin ameliorates aortic valve calcification via the regulation of circular RNA CircRIC3/miR-204-5p/DPP4 signaling in valvular interstitial cells," *Journal of Pineal Research*, vol. 69, no. 2, Article ID e12666, 2020.
- [2] G. Voicu, D. Rebleanu, C. A. Constantinescu et al., "Nanopolyplexes mediated transfection of runx2-shRNA mitigates the osteodifferentiation of human valvular interstitial cells," *Pharmaceutics*, vol. 12, no. 6, p. 507, 2020.
- [3] A. Youssef, J. R. Clark, M. L. Koschinsky, and M. B. Boffa, "Lipoprotein(a): expanding our knowledge of aortic valve narrowing," *Trends in Cardiovascular Medicine*, vol. 31, no. 5, pp. 305–311, 2021.
- [4] S. Yadgir, C. O. Johnson, V. Aboyans et al., "Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases," *Circulation*, vol. 141, no. 21, pp. 1670–1680, 1990.
- [5] R. A. Nishimura, C. M. Otto, R. O. Bonow et al., "2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines," *Circulation*, vol. 135, no. 25, pp. e1159–e1195, 2017.
- [6] B. Alushi, L. Curini, M. R. Christopher et al., "Calcific aortic valve disease-natural history and future therapeutic strategies," *Frontiers in Pharmacology*, vol. 11, p. 685, 2020.
- [7] The ENCODE Project Consortium, "An integrated encyclopedia of DNA elements in the human genome," *Nature*, vol. 489, no. 7414, pp. 57–74, 2012.
- [8] Y. Wang, J. Liu, J. Ma et al., "Exosomal circRNAs: biogenesis, effect and application in human diseases," *Molecular Cancer*, vol. 18, no. 1, p. 116, 2019.
- [9] S. Meng, H. Zhou, Z. Feng et al., "CircRNA: functions and properties of a novel potential biomarker for cancer," *Molecular Cancer*, vol. 16, no. 1, p. 94, 2017.
- [10] L. Salmena, L. Poliseno, Y. Tay, L. Kats, and P. P. Pandolfi, "A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?" *Cell*, vol. 146, no. 3, pp. 353–358, 2011.
- [11] V. N. S. Garikipati, S. K. Verma, Z. Cheng et al., "Circular RNA CircFndc3b modulates cardiac repair after myocardial infarction via FUS/VEGF-A axis," *Nature Communications*, vol. 10, no. 1, p. 4317, 2019.
- [12] W. W. Du, J. Xu, W. Yang et al., "A neuroigin isoform translated by circNlgn contributes to cardiac remodeling," *Circulation Research*, vol. 129, no. 5, pp. 568–582, 2021.
- [13] F. Huang, J. Mai, J. Chen, Y. He, and X. Chen, "Non-coding RNAs modulate autophagy in myocardial ischemia-reperfusion injury: a systematic review," *Journal of Cardiothoracic Surgery*, vol. 16, no. 1, p. 140, 2021.
- [14] C. Yu, D. Wu, C. Zhao, and C. Wu, "CircRNA TGFBR2/MiR-25-3p/TWIST1 axis regulates osteoblast differentiation of human aortic valve interstitial cells," *Journal of Bone and Mineral Metabolism*, vol. 39, no. 3, pp. 360–371, 2021.
- [15] G. K. Smyth, J. Michaud, and H. S. Scott, "Use of within-array replicate spots for assessing differential expression in microarray experiments," *Bioinformatics*, vol. 21, no. 9, pp. 2067–2075, 2005.
- [16] L. Yang, S. Wang, Q. Zhang et al., "Clinical significance of the immune microenvironment in ovarian cancer patients," *Mol Omics*, vol. 14, no. 5, pp. 341–351, 2018.
- [17] S. Wang, Y. Xiong, Q. Zhang et al., "Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer," *Briefings in Bioinformatics*, vol. 22, no. 4, p. bbaa311, 2021.
- [18] S. Wang, Q. Zhang, C. Yu, Y. Cao, Y. Zuo, and L. Yang, "Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer," *Briefings in Bioinformatics*, vol. 22, no. 2, pp. 2020–2031, 2021.
- [19] D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," *Nature Protocols*, vol. 4, no. 1, pp. 44–57, 2009.
- [20] E. The, Q. Yao, P. Zhang et al., "Mechanistic roles of matrilin-2 and klotho in modulating the inflammatory activity of human aortic valve cells," *Cells*, vol. 9, no. 2, p. 385, 2020.
- [21] P. Dutta, K. M. Kodigepalli, S. LaHaye et al., "KPT-330 prevents aortic valve calcification via a novel C/EBP β signaling pathway," *Circulation Research*, vol. 128, no. 9, pp. 1300–1316, 2021.
- [22] P. Dutta and J. Lincoln, "Calcific aortic valve disease: a developmental biology perspective," *Current Cardiology Reports*, vol. 20, no. 4, p. 21, 2018.
- [23] Y. Tay, J. Rinn, and P. P. Pandolfi, "The multilayered complexity of ceRNA crosstalk and competition," *Nature*, vol. 505, no. 7483, pp. 344–352, 2014.
- [24] M. Vadana, S. Cecoltan, L. Ciortan et al., "Molecular mechanisms involved in high glucose-induced valve calcification in a 3D valve model with human valvular cells," *Journal of Cellular and Molecular Medicine*, vol. 24, no. 11, pp. 6350–6361, 2020.
- [25] J. Chen, L. Che, C. Xu et al., "Cardio-facio-cutaneous syndrome-associated pathogenic MAP2K1 variants activate autophagy," *Gene*, vol. 733, Article ID 144369, 2020.
- [26] L. Yang, D. Wu, M. Li et al., "Upregulation of microRNA-195 ameliorates calcific aortic valve disease by inhibiting VWF via suppression of the p38-MAPK signaling pathway," *International Journal of Cardiology*, vol. 309, pp. 101–107, 2020.
- [27] B. Wu, Y. Wang, F. Xiao, J. T. Butcher, K. E. Yutzey, and B. Zhou, "Developmental mechanisms of aortic valve malformation and disease," *Annual Review of Physiology*, vol. 79, no. 1, pp. 21–41, 2017.
- [28] Y. Guo, Y. Chen, H. Liu, and W. Yan, "Alpinetin inhibits oral squamous cell carcinoma proliferation via miR-211-5p upregulation and notch pathway deactivation," *Nutrition and Cancer*, vol. 72, no. 5, pp. 757–767, 2020.
- [29] G. A. Walker, K. S. Masters, D. N. Shah, K. S. Anseth, and L. A. Leinwand, "Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease," *Circulation Research*, vol. 95, no. 3, pp. 253–260, 2004.

- [30] Q. Yao, R. Song, L. Ao, J. C. Cleveland, D. A. Fullerton, and X. Meng, "Neurotrophin 3 upregulates proliferation and collagen production in human aortic valve interstitial cells: a potential role in aortic valve sclerosis," *American Journal of Physiology - Cell Physiology*, vol. 312, no. 6, pp. C697–C706, 2017.
- [31] C. M. Tigaret, T.-C. E. Lin, E. R. Morrell et al., "Neurotrophin receptor activation rescues cognitive and synaptic abnormalities caused by hemizygoty of the psychiatric risk gene *Cacna1c*," *Molecular Psychiatry*, vol. 26, no. 6, pp. 1748–1760, 2021.
- [32] R. L. Wilson, C. B. Sylvester, D. C. Wiltz et al., "The ryanodine receptor contributes to the lysophosphatidylcholine-induced mineralization in valvular interstitial cells," *Cardiovascular engineering and technology*, vol. 11, no. 3, pp. 316–327, 2020.
- [33] M. Matsui, R. Bouchareb, M. Storto et al., "Increased Ca²⁺ influx through CaV1.2 drives aortic valve calcification," *JCI insight*, vol. 7, no. 5, Article ID e155569, 2022.
- [34] J. Hjortnaes, K. Shapero, C. Goettsch et al., "Valvular interstitial cells suppress calcification of valvular endothelial cells," *Atherosclerosis*, vol. 242, no. 1, pp. 251–260, 2015.
- [35] A. Boratkó, P. Gergely, and C. Csontos, "RACK1 is involved in endothelial barrier regulation via its two novel interacting partners," *Cell Communication and Signaling*, vol. 11, no. 1, p. 2, 2013.
- [36] D. J. Huk, B. F. Austin, T. E. Horne et al., "Valve endothelial cell-derived Tgf β 1 signaling promotes nuclear localization of Sox9 in interstitial cells associated with attenuated calcification," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 36, no. 2, pp. 328–338, 2016.
- [37] A. E. Schade, M. Fischer, and J. A. R. B. DeCaprio, "RB, p130 and p107 differentially repress G1/S and G2/M genes after p53 activation," *Nucleic Acids Research*, vol. 47, no. 21, pp. 11197–11208, 2019.
- [38] Z.-R. Gu and W. Liu, "The LncRNA AL161431.1 targets miR-1252-5p and facilitates cellular proliferation and migration via MAPK signaling in endometrial carcinoma," *European Review for Medical and Pharmacological Sciences*, vol. 24, no. 5, pp. 2294–2302, 2020.
- [39] A. Gutiérrez, C. Contreras, A. Sánchez, and D. Prieto, "Role of phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and protein kinase C (PKC) in calcium signaling pathways linked to the α 1-adrenoceptor in resistance arteries," *Frontiers in Physiology*, vol. 10, p. 55, 2019.
- [40] F. Xie, F. Li, R. Li et al., "Inhibition of PP2A enhances the osteogenic differentiation of human aortic valvular interstitial cells via ERK and p38 MAPK pathways," *Life Sciences*, vol. 257, Article ID 118086, 2020.
- [41] M. Hara, T. Takahashi, C. Mitsumasu et al., "Disturbance of cardiac gene expression and cardiomyocyte structure predisposes *Mecp2*-null mice to arrhythmias," *Scientific Reports*, vol. 5, no. 1, Article ID 11204, 2015.
- [42] M. Neupane, A. P. Clark, S. Landini et al., "MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy," *Cancer Discovery*, vol. 6, no. 1, pp. 45–58, 2016.
- [43] P. Sahadevan and B. G. Allen, "MK5: a novel regulator of cardiac fibroblast function?" *IUBMB Life*, vol. 69, no. 10, pp. 785–794, 2017.
- [44] J. D. Hutcheson, E. Aikawa, and W. D. Merryman, "Potential drug targets for calcific aortic valve disease," *Nature Reviews Cardiology*, vol. 11, no. 4, pp. 218–231, 2014.